CD163, CD206, IL-10 and STAT6 are regarded as markers of M2 macrophages that promoted tumor progression28, suggesting that targeting M2 macrophages in the glioma TME may be an alternative therapeutic strategy. Here, MRC1 is linked to neoplasm.